Trials / Completed
CompletedNCT04207775
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in EGFR Mutation-Positive, Locally Advanced or Metastatic Chinese NSCLC Patients, Who Have Progressed From First-line EGFR-TKI Therapy (PISCES)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.
Detailed description
The objectives of this study are to assess molecular testing, treatment patterns, and associated clinical outcomes among patients with epidermal growth factor receptor (EGFR) mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed from first-line EGFR-TKI (tyrosine kinase inhibitor) therapy. This study is descriptive in nature and does not attempt to test any specific a priori hypotheses
Conditions
Timeline
- Start date
- 2020-03-30
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
- First posted
- 2019-12-23
- Last updated
- 2024-07-12
Locations
16 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04207775. Inclusion in this directory is not an endorsement.